Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study, sending its shares up over 15% in premarket trading. The drug, tinlarebant, ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

Discover why Ideaya Biosciences, Inc. is rated a Buy for its promising oncology pipeline and upcoming catalysts. Click for my ...

Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, announced ...

A 42-year-old man presented to the emergency department with complaints of difficulty ambulating, fatigue, unintentional ...

Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...

Advantages: Specifically designed for infants who may not cooperate during examinations, this lens is crucial for detecting congenital eye diseases in newborns, facilitating early diagnosis and ...

Her doctors say it's the first case of blindness being the only sign of metastatic lung cancer ever found in someone with no clear risk factors. Reading time 2 minutes A woman’s blindness in her right ...